

AMENDMENTS TO THE CLAIMS

Please cancel claim 1 and amend claims 2-9, 11-19, 58-59 and 66, without prejudice or admission, so that the pending claims are as indicated in the following marked-up listing of the claims:

1. (Canceled)
2. (Currently Amended) A parenteral vaccine formulation according to ~~claim 1~~ claim 66, wherein the adjuvant is selected from inorganic salts.
3. (Canceled)
4. (Currently Amended) A parenteral vaccine formulation according to ~~claim 1~~ claim 66, wherein the adjuvant is selected from salts formed with oxides, peroxides, hydroxides, carbonates, phosphates, pyrophosphates, hydrogenphosphates, dihydrogenphosphates, sulphates, and/or silicates, and hydrates thereof.
5. (Currently Amended) A parenteral vaccine formulation according to ~~claim 1~~ claim 66, wherein the adjuvant is selected from salts formed between Mg, Ca, Ba, Ti, or Zr, and oxide, peroxide, hydroxide, and/or carbonate, and hydrates thereof.
6. (Currently Amended) A parenteral vaccine formulation according to ~~claim 1~~ claim 66, wherein the adjuvant is selected from salts formed between magnesium and oxide, peroxide, hydroxide, and/or carbonate, calcium and oxide, peroxide, hydroxide, and/or carbonate, barium and oxide, peroxide, hydroxide, and/or carbonate, titanium and oxide, peroxide, hydroxide, and/or carbonate, and zirconium and oxide, peroxide, hydroxide, and/or carbonate, and hydrates thereof.

7. (Currently Amended) A parenteral vaccine formulation according to ~~claim 1~~ claim 66, wherein the adjuvant is selected from magnesium hydroxide, magnesium carbonate hydroxide pentahydrate, titanium dioxide, calcium carbonate, barium hydroxide, barium peroxide, barium carbonate, barium sulphate, beryllium oxide, calcium sulphate, calcium silicate, dicalcium silicate, tricalcium silicate, calcium pyrophosphate, calcium peroxide, calcium hydroxide, tricalcium phosphate, calcium hydrogenphosphate, calcium dihydrogenphosphate, calcium sulphate dihydrate, magnesium carbonate, magnesium oxide, magnesium dioxide, magnesium sulphate, trimagnesium phosphate, magnesium silicate, dimagnesium trisilicate, magnesium trisilicate, titanium disulphate, zirconium dioxide, zirconium hydroxide, zirconium sulphate, strontium peroxide, and strontium carbonate.

8. (Currently Amended) A parenteral vaccine formulation according to ~~claim 4~~ claim 66, wherein the adjuvant is selected from magnesium hydroxide, magnesium carbonate hydroxide pentahydrate, and titanium dioxide.

9. (Currently Amended) A parenteral vaccine formulation according to claim 1 claim 66 further comprising an additional adjuvant.

10. (Previously Presented) A parenteral vaccine formulation according to claim 9, wherein the additional adjuvant is selected from saponins such as Quil A and Qs-21, MF59, MPL, PLG, PLGA, and aluminium salts, with the proviso that the salt is not magnesium hydroxide in combination with aluminium hydroxide or aluminium oxide.

11. (Currently Amended) A parenteral vaccine formulation according to ~~claim 1~~ claim 66, further comprising pharmaceutically acceptable excipients and/or carriers.
12. (Currently Amended) A parenteral vaccine formulation according to ~~claim 1~~ claim 66, further comprising diluents, buffers, suspending agents, solubilising agents, pH-adjusting agents, dispersing agents, and/or colorants.
13. (Currently Amended) A parenteral vaccine formulation according to ~~claim 1~~ claim 66, for intravenous, intramuscular, intraarticular, subcutaneous, intradermal, epicutaneous, and intraperitoneal administration.
14. (Currently Amended) A parenteral vaccine formulation according to ~~claim 1~~ claim 66, wherein the cation of the adjuvant is present in an amount of from about 0.0004 to about 120 M.
15. (Currently Amended) A parenteral vaccine formulation according to ~~claim 1~~ claim 66, wherein the cation of the adjuvant is present in an amount of from about 0.008 to about 6 M.
16. (Currently Amended) A parenteral vaccine formulation according to ~~claim 1~~ claim 66, wherein the adjuvant is magnesium hydroxide.
17. (Currently Amended) A parenteral vaccine formulation according to ~~claim 1~~ claim 66, wherein the adjuvant is magnesium carbonate hydroxide pentahydrate.
18. (Currently Amended) A parenteral vaccine formulation according to ~~claim 1~~ claim 66, wherein the adjuvant is titanium dioxide.
19. (Currently Amended) A parenteral vaccine formulation according to ~~claim 1~~ claim 66, wherein the adjuvant is a combination of magnesium

hydroxide and magnesium carbonate hydroxide pentahydrate, magnesium hydroxide and titanium dioxide, magnesium carbonate hydroxide pentahydrate and titanium dioxide, or magnesium hydroxide, magnesium carbonate hydroxide pentahydrate, and titanium dioxide.

20. (Previously Presented) A parenteral vaccine formulation according to claim 16 further comprising an additional adjuvant selected from saponins such as Quil A and Qs-21, MF59, MPL, PLG, PLGA, and aluminium salts, with the proviso that the salt is not magnesium hydroxide in combination with aluminium hydroxide or aluminium oxide.

21-57. (Canceled)

58. (Currently Amended) A method of generating an immune response in a subject comprising administering to the subject a parenteral vaccine formulation according to ~~claim 1~~ claim 66.

59. (Currently Amended) A method for vaccination or treatment of a vertebrate including a human being comprising administering a vaccine formulation according to ~~claim 1~~ claim 66.

60-64. (Canceled)

65. (Currently Amended) A parenteral vaccine formulation according to ~~claim 1~~ claim 66, wherein the cation of the adjuvant is present in an amount of from about 0.004 to about 12 M.

66. (Previously Presented) A parenteral vaccine formulation comprising:

- (a) at least one immunogenic substance selected from the group consisting of antigens, allergens, allergoids, peptides, proteins, haptens, carbohydrate, PNA and RNA; and

